Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431234 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3050102 | 0.83 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7237076 | 0.82 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6602521 | 0.81 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4055639 | 0.80 | MAPT (0.50) | — | |
| SCHEMBL7098510 | 0.79 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4940273 | 0.79 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL5658557 | 0.79 | CHRNB2 (0.65) | CHRNB2CHRNA4 | |
| SCHEMBL4930731 | 0.77 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4311522 | 0.77 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706739-B2 | TREATING ENTEROVIRUS INFECTION | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2004-03-16 | — | — | US | disclosed |
| US-20030087936-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087936-A1 | Imidazolidinone compounds | EIF2AK2, ZC3HAV1, EMG1 | CHRNB2 4688/4885CHRNA4 4585/4885CHRNB4 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.